Bai Xiuying, Dinghong Qiu, Miao Dengshun, Goltzman David, Karaplis Andrew C
Division of Endocrinology, Dept. of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote Ste. Catherine Rd., Montreal, Quebec, Canada H3T 1E2.
Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E79-88. doi: 10.1152/ajpendo.90539.2008. Epub 2008 Nov 4.
Transgenic mice overexpressing fibroblast growth factor (FGF23) (R176Q) (F(Tg)) exhibit biochemical {hypophosphatemia, phosphaturia, abnormal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] metabolism} and skeletal (rickets and osteomalacia) abnormalities attributable to FGF23 action. In vitro studies now implicate the aging-related factor Klotho in the signaling mechanism of FGF23. In this study, we used a mouse genetic approach to validate in vivo the pivotal role of Klotho in the metabolic and skeletal derangements associated with FGF23 (R176Q) overexpression. To this end, we crossed mice heterozygous for the hypomorphic Klotho allele (Kl(+/-)) to F(Tg) mice and obtained F(Tg) transgenic mice homozygous for the Kl-hypomorphic allele (F(Tg)/Kl(-/-)). Mice were killed on postnatal day 50, and serum and tissues were procured for analysis and comparison with F(Tg), wild-type, and Kl(-/-) controls. From 4 wk onward, F(Tg)/Kl(-/-) mice were clearly distinguishable from F(Tg) mice and exhibited a striking phenotypic resemblance to the Kl(-/-) controls. Serum analysis for calcium, phosphorus, parathyroid hormone, 1,25(OH)(2)D(3), and alkaline phosphatase activity confirmed the biochemical similarity between the F(Tg)/Kl(-/-) and Kl(-/-) mice and their distinctness from the F(Tg) controls. The characteristic skeletal changes associated with FGF23 (R176Q) overexpression were also dramatically reversed by the absence of Klotho. Hence the wide, unmineralized growth plates and the osteomalacic abnormalities apparent in trabecular and cortical bone were completely reversed in the F(Tg)/Kl(-/-) mice. Nevertheless, independent actions of Klotho on bone were suggested as manifested by alterations in mineralized bone, and in cortical bone volume which were observed in both the Kl(-/-) and F(Tr)/Kl(-/-) mutants. In summary, our findings substantiate in vivo the essential role of Klotho in the mechanism of action of FGF23 in view of the fact that Klotho ablation converts the biochemical and skeletal manifestations resulting from FGF23 overexpression to a phenotype consistent with Klotho deficiency.
过表达成纤维细胞生长因子(FGF23)(R176Q)的转基因小鼠(F(Tg))表现出生物化学方面的 {低磷血症、磷尿症、异常的1,25-二羟维生素D3 [1,25(OH)2D3] 代谢} 以及归因于FGF23作用的骨骼(佝偻病和骨软化症)异常。目前的体外研究表明,与衰老相关的因子α-klotho参与了FGF23的信号传导机制。在本研究中,我们采用小鼠遗传学方法在体内验证α-klotho在与FGF23(R176Q)过表达相关的代谢和骨骼紊乱中的关键作用。为此,我们将携带低表达α-klotho等位基因的杂合小鼠(Kl(+/-))与F(Tg)小鼠杂交,获得了纯合低表达α-klotho等位基因的F(Tg)转基因小鼠(F(Tg)/Kl(-/-))。在出生后第50天处死小鼠,采集血清和组织进行分析,并与F(Tg)、野生型和Kl(-/-)对照进行比较。从4周龄起,F(Tg)/Kl(-/-)小鼠就明显不同于F(Tg)小鼠,并且在表型上与Kl(-/-)对照有显著相似性。对钙、磷、甲状旁腺激素、1,25(OH)2D3和碱性磷酸酶活性的血清分析证实了F(Tg)/Kl(-/-)和Kl(-/-)小鼠之间的生物化学相似性以及它们与F(Tg)对照的差异。与FGF23(R176Q)过表达相关的特征性骨骼变化也因α-klotho的缺失而显著逆转。因此,F(Tg)/Kl(-/-)小鼠中明显的宽阔、未矿化的生长板以及小梁骨和皮质骨中的骨软化异常完全得到了逆转。然而,α-klotho对骨骼的独立作用通过矿化骨和皮质骨体积的改变得以体现,这在Kl(-/-)和F(Tr)/Kl(-/-)突变体中均有观察到。总之,鉴于α-klotho缺失将FGF23过表达导致的生物化学和骨骼表现转变为与α-klotho缺乏一致的表型,我们的研究结果在体内证实了α-klotho在FGF23作用机制中的重要作用。